Johnson & Johnson’s offer worth US$280 a share
ZURICH: US healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a US$30bil all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!